Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death of advanced squamous lung cancer

On March 21, 2018, Posted by , In News, By , , With Comments Off on Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death of advanced squamous lung cancer

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met…

Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

On March 20, 2018, Posted by , In News, By ,, , With Comments Off on Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

Boehringer Ingelheim and Vanderbilt University announced the expansion of their successful existing collaboration to develop novel anti-cancer compounds. The expanded research partnership will focus on the discovery and development of new chemical therapeutics targeting the pro-survival protein MCL1 as a potential therapy against MCL1 dependent cancers. This is the third…

Sciomics: Solving Alzheimers with this company’s new approach?

On March 14, 2018, Posted by , In News, By , , With Comments Off on Sciomics: Solving Alzheimers with this company’s new approach?

Labiotech.eu media recently profiled our member Sciomics, a German Cancer Research Center (DKFZ) spin-off founded in 2013 by a team of researchers led by Dr. Christoph Schröder and Dr. Jörg Hoheisel. Sciomics has developed antibody microarrays as a tool for analyzing complex protein samples. Using their expertise, they are able to address…

BioMed X and Roche announce research collaboration in the field of immunology

On March 13, 2018, Posted by , In News, By , , With Comments Off on BioMed X and Roche announce research collaboration in the field of immunology

BioMed X announced today the initiation of a new research collaboration with F. Hoffmann-La Roche Ltd in the field of immunology. Within the framework of the agreement, BioMed X will launch a global call for applications to establish a new biomedical research group in Heidelberg. The main objective of the…

New EMBL spinoff company Velabs Therapeutics to accelerate antibody discovery

On March 8, 2018, Posted by , In News, By , , With Comments Off on New EMBL spinoff company Velabs Therapeutics to accelerate antibody discovery

An established proprietary microfluidics technology from the European Molecular Biology Laboratory (EMBL) allows for fast screening of antibodies from natural sources and even difficult targets. With the startup company Velabs Therapeutics, launched by EMBL and its technology transfer arm EMBLEM Technology Transfer GmbH (EMBLEM) together with private investors, the advantages…

GSK: New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age

On March 6, 2018, Posted by , In News, By , , With Comments Off on GSK: New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age

GSK today announced new data published in The Lancet Child & Adolescent Health from a Phase III clinical trial with Fluarix Tetra (inactivated quadrivalent influenza vaccine [IIV4]) which prevented influenza A and B in children six to 35 months of age. Vaccine efficacy was highest against moderate-to-severe influenza, where the…